SBT 77 7101
Alternative Names: SBT-77-7101Latest Information Update: 26 Apr 2024
At a glance
- Originator Sonoma Biotherapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Hidradenitis suppurativa; Rheumatoid arthritis
Most Recent Events
- 12 Apr 2024 Phase-I clinical trials in Hidradenitis suppurativa in USA (Parenteral) (NCT06361836)
- 16 Jan 2024 Phase-I clinical trials in Rheumatoid arthritis in USA (Parenteral) (NCT06201416)
- 10 Nov 2023 Pharmacodynamics data from preclinical trial in Rheumatoid arthritis presented at the ACR Convergence 2023